
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549**

FORM 8-K

**CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported) March 21, 2008

Nabi Biopharmaceuticals

(Exact Name of Registrant as Specified in Its Charter)

Delaware

(State or Other Jurisdiction of Incorporation)

000-04829

(Commission File Number)

59-1212264

(IRS Employer Identification No.)

12276 Wilkins Avenue, Rockville, MD

(Address of Principal Executive Offices)

20852

(Zip Code)

(301) 770-3099

(Registrant's Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers

On March 21, 2008, Jordan I. Siegel resigned as Senior Vice President, Finance and Administration, Chief Financial Officer, Chief Accounting Officer and Treasurer of Nabi Biopharmaceuticals (the "Company"), effective March 28, 2008. Mr. Siegel intends to continue to serve as Chief Financial Officer of Biotest Pharmaceuticals Corporation ("Biotest"), a position he has held since December 4, 2007. On that date, Biotest acquired the Company's Biologics Strategic Business Unit, manufacturing facilities, Boca Raton, Florida headquarters and nine plasma centers. The Company is in the process of a search for a successor to Mr. Siegel.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NABI BIOPHARMACEUTICALS

Date: March 27, 2008

By: /s/ Raafat E.F. Fahim

Name: Raafat E.F. Fahim

Title: President and Chief Executive Officer